CERo Therapeutics is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel therapies for central nervous system disorders. The company focuses on small-molecule modulators that selectively target key neurotransmitter receptors and signaling pathways implicated in neurodegenerative and neuroinflammatory conditions. By leveraging a proprietary platform for receptor profiling and medicinal chemistry optimization, CERo aims to advance pipeline candidates with differentiated mechanisms of action to address areas of high unmet medical need.
The lead asset in CERo’s pipeline is an orally administered compound designed to restore synaptic homeostasis and reduce neuroinflammation in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Preclinical studies have demonstrated favorable pharmacokinetic properties, robust blood-brain barrier penetration, and target engagement in relevant animal models. In addition to its lead program, CERo is progressing back-up candidates and discovery stage efforts targeting Parkinson’s disease, chronic pain, and traumatic brain injury under its internal research framework.
Founded in 2012 and headquartered in Cambridge, Massachusetts, CERo Therapeutics collaborates with academic institutions and contract research organizations in North America and Europe. The company has established partnerships to support clinical trial execution, biomarker development, and regulatory interactions across multiple jurisdictions. Through these strategic alliances, CERo seeks to accelerate the translation of its preclinical findings into human studies and to ensure a robust path toward regulatory approval.
Leadership at CERo includes President and Chief Executive Officer Dr. Alice Martin, a neuroscientist with over two decades of experience in CNS drug discovery, and Chief Medical Officer Dr. Robert Chen, formerly of leading global pharmaceutical firms. The senior management team is complemented by a scientific advisory board comprised of experts in neuropharmacology, neurology, and translational medicine. Under this leadership, CERo is positioned to advance its mission of delivering innovative treatments that can improve outcomes for patients suffering from debilitating neurological diseases.
AI Generated. May Contain Errors.
Free CERO Stock Alerts